These effects were not seen with reverse transcriptase inhibitors
Efavirenz is the non-nucleoside reverse transcriptase inhibitor
of choice with rifampicin.
This effect was not seen in patients who were not exposed to protease inhibitors and was not associated with exposure to non-nucleoside reverse transcriptase inhibitors
, although patients were not exposed to this class of drug for as long.
nucleoside analogue reverse transcriptase inhibitors
(NRTIs), gp120 inhibitors, protease inhibitors, acetylcholinesterase inhibitors.
Reverset is a nucleoside analog reverse transcriptase inhibitor
that is being developed as a once-daily oral HIV therapy by Incyte Corporation and Pharmasset, Inc.
Even though other studies showed that elevations in triglyceride and cholesterol and body shape changes were also seen with the other classes of drugs and not just the protease inhibitors, the field had moved to using a non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based regimen as part of first-line therapy.
Nucleoside/Nucleotide reverse transcriptase inhibitors
(nukes): These medications interfere with viral reverse transcriptase by acting as "fake building blocks" that disrupt the creation of proviral DNA needed to take over the infected cell to build new viruses (see #2 in diagram).
The most common combinations of two nucleoside reverse transcriptase inhibitors
were didanosine plus stavudine (52% of patients) and zidovudine plus lamivudine (42%).
These drugs are other nucleoside reverse transcriptase inhibitors
such as lamivudine, and nonnucleoside reverse transcriptase inhibitors
such as nevirapine, and protease inhibitors such as indinavir and ritonavir.
The development of protease inhibitor drugs last year - and the discovery that their potency was enhanced when combined with an earlier class of drugs called reverse transcriptase inhibitors
- meant that for the first time since the epidemic exploded in the early 1980s, patients can dare to hope.
It is "active against a variety of HIV-1 strains and HIV-2, including strains that have proven themselves resistant to AZT [zidovudine] and other reverse transcriptase inhibitors
A single dose of tenofovir and emtricitabine at delivery reduced resistance to nonnucleoside reverse transcriptase inhibitors
at 6 weeks after delivery by half.